Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 14/20 | 1.00 |
| ▸ | LPAR1 | Q92633 | 13/20 | 1.00 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.72 |
| ▸ | LPAR5 | Q9H1C0 | 6/20 | 0.69 |
| ▸ | LPAR6 | P43657 | 5/20 | 0.56 |
| ▸ | LPAR4 | Q99677 | 5/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.51 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29458233 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL29353224 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL31439420 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL30443866 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL31198159 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL10896195 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL2813163 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL5055004 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL496845 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL27734843 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249055-A1 | CLOFARABINE PHOSPHOLIPID DERIVATIVES | HEIDELBERG PHARMA AG (DE) | 2010-09-30 | — | — | US | disclosed |
| EP-2231690-A2 | CLOFARABINE DIETHERPHOSPHOLIPID DERIVATIVES | Heidelberg Pharma AG (DE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009074253-A2 | CLOFARABINE PHOSPHOLIPID DERIVATIVES | HEIDELBERG PHARMA AG (DE) | 2009-06-18 | — | — | WO | disclosed |
| EP-2070938-A1 | Clofarabine dietherphospholipid derivatives | Heidelberg Pharma AG (DE) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008052722-A2 | USE OF RIBAVIRIN-CONJUGATES AS AN ANTI-VIRAL DRUG | HEIDELBERG PHARMA AG (DE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249055-A1 | CLOFARABINE PHOSPHOLIPID DERIVATIVES | PHOSPHO1, ABHD16A, SGMS2 | LPAR3 307/4885LPAR1 315/4885LPAR2 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.